Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol
Autore:
Vega, GL; Von Bergmann, K; Grundy, SM; Blumenschein, S; Carter, NB; Laeis, P; Lindenthal, B; Von Bergmann, J; Simatupang, A; Lutjohann, D; Adams-Huet, B;
Indirizzi:
Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75235 USA Univ Texas Dallas TX USA 75235 Ctr, Ctr Human Nutr, Dallas, TX 75235 USA Univ Texas, SW Med Ctr, Dept Clin Nutr, Dallas, TX 75235 USA Univ Texas Dallas TX USA 75235 Ctr, Dept Clin Nutr, Dallas, TX 75235 USA Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA Univ Texas Dallas TX USA 75235 r, Dept Internal Med, Dallas, TX 75235 USA Univ Texas, SW Med Ctr, Dept Paediat, Dallas, TX 75235 USA Univ Texas Dallas TX USA 75235 ed Ctr, Dept Paediat, Dallas, TX 75235 USA Vet Affairs Med Ctr, Dallas, TX 75216 USA Vet Affairs Med Ctr Dallas TX USA 75216 irs Med Ctr, Dallas, TX 75216 USA Univ Bonn, Sch Med, Dept Clin Pharmacol, D-5300 Bonn, Germany Univ Bonn Bonn Germany D-5300 Dept Clin Pharmacol, D-5300 Bonn, Germany
Titolo Testata:
JOURNAL OF INTERNAL MEDICINE
fascicolo: 1, volume: 246, anno: 1999,
pagine: 1 - 9
SICI:
0954-6820(199907)246:1<1:EOLOTM>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
LIPID-LOWERING DRUG; FAMILIAL HYPERCHOLESTEROLEMIA; SITOSTANOL; ABSORPTION; K12.148; SERUM; HYPOALPHALIPOPROTEINEMIA; LOVASTATIN; TURNOVER; THERAPY;
Keywords:
apolipoprotein metabolism; hypercholesterolemia; lifibrol;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Vega, GL 5323 Harry Hines Blvd, Dallas, TX 75235 USA 5323 Harry Hines Blvd Dallas TX USA 75235 , Dallas, TX 75235 USA
Citazione:
G.L. Vega et al., "Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol", J INTERN M, 246(1), 1999, pp. 1-9

Abstract

Lifibrol is a powerful cholesterol-lowering drug of unknown mechanism of action, This investigation was carried out to determine whether the major action of lifibrol is to enhance clearance of low density lipoproteins (LDL) through the LDL-receptor pathway, and if so, whether the drug exerts its action by altering the excretion of bile acids (acidic steroids), the absorption of cholesterol, or the synthesis of cholesterol, In a first study, in two patients with complete absence of LDL receptors, lifibrol therapy had essentially no effect on plasma LDL concentrations: in two others who had a marked reduction in LDL-receptor activity, response to the drug was attenuated. These findings suggest that lifibrol requires an intact LDL-receptor pathway to exert its action, In a second study, in patients with primary moderate hypercholesterolemia, isotope kinetic studies showed that lifibrol enhanced the fractional catabolic rate of LDL-apolipoprotein B (apo B). but had no effect on transport rates of LDL; these observations likewise support the probability that lifibrol acts mainly to increase the activity of the LDL-receptor pathway. However, in a third study in hypercholesterolemic patients, lifibrol therapy failed to increase acidic steroid excretion, inhibitcholeslerol absorption, or reduce net cholesterol balance, Furthermore, lifibrol treatment did not significantly reduce urinary excretion of mevalonic acid. In contrast, in a parallel study, simvastatin therapy, which is known to inhibit cholesterol synthesis, gave the expected decrease in net cholesterol balance and reduction in urinary excretion of mevalonic acid, Thus,lifibrol, like statins, appears to increase the activity of LDL receptors;but in contrast to findings with statins, it was not possible to detect a significant decreased synthesis of cholesterol, either from balance studiesor from urinary excretion of mevalonic acid. This finding raises the possibility that lifibrol activates the LDL-receptor pathway through a differentmechanisms which remains to be determined.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 04:03:33